@article{f0f6e44bc9714a84940b3d0a75fe93f7,
title = "Dynamic Control of Enhancer Repertoires Drives Lineage and Stage-Specific Transcription during Hematopoiesis",
abstract = "Enhancers are the primary determinants of cell identity, but the regulatory components controlling enhancer turnover during lineage commitment remain largely unknown. Here we compare the enhancer landscape, transcriptional factor occupancy, and transcriptomic changes in human fetal and adult hematopoietic stem/progenitor cells and committed erythroid progenitors. We find that enhancers are modulated pervasively and direct lineage- and stage-specific transcription. GATA2-to-GATA1 switch is prevalent at dynamic enhancers and drives erythroid enhancer commissioning. Examination of lineage-specific enhancers identifies transcription factors and their combinatorial patterns in enhancer turnover. Importantly, by CRISPR/Cas9-mediated genomic editing, we uncover functional hierarchy of constituent enhancers within the SLC25A37 super-enhancer. Despite indistinguishable chromatin features, we reveal through genomic editing the functional diversity of several GATA switch enhancers in which enhancers with opposing functions cooperate to coordinate transcription. Thus, genome-wide enhancer profiling coupled with in situ enhancer editing provide critical insights into the functional complexity of enhancers during development.",
author = "Jialiang Huang and Xin Liu and Dan Li and Zhen Shao and Hui Cao and Yuannyu Zhang and Eirini Trompouki and Bowman, {Teresa V.} and Zon, {Leonard I.} and Yuan, {Guo Cheng} and Orkin, {Stuart H.} and Jian Xu",
note = "Funding Information: We thank Matthew Canver, Daniel Bauer, Luca Pinello, and members of the Orkin laboratory for assistance and discussion, John Stamatoyannopoulos for assistance with DNase-seq, and Ben van Handel and Hanna Mikkola for providing the fetal CD34+ cells. This work was supported by NIH/NHLBI grant R01HL119099 (to G.C.Y and S.H.O.). L.I.Z and S.H.O. are Investigators of the Howard Hughes Medical Institute (HHMI). This work was also supported by NIH/NIDDK grants K01DK093543 and R03DK101665, by a Cancer Prevention and Research Institute of Texas (CPRIT) New Investigator Award (RR140025), by the American Cancer Society (IRG-02-196) award and the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, and by an American Society of Hematology Scholar Award (to J.X.). Funding Information: We thank Matthew Canver, Daniel Bauer, Luca Pinello, and members of the Orkin laboratory for assistance and discussion, John Stamatoyannopoulos for assistance with DNase-seq, and Ben van Handel and Hanna Mikkola for providing the fetal CD34+ cells. This work was supported by NIH/NHLBI grant R01HL119099 (to G.C.Y and S.H.O.). L.I.Z and S.H.O. are Investigators of the Howard Hughes Medical Institute (HHMI). This work was also supported by NIH/NIDDK grants K01DK093543 and R03DK101665 , by a Cancer Prevention and Research Institute of Texas (CPRIT) New Investigator Award ( RR140025 ), by the American Cancer Society ( IRG-02-196 ) award and the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, and by an American Society of Hematology Scholar Award (to J.X.). Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",
year = "2016",
month = jan,
day = "11",
doi = "10.1016/j.devcel.2015.12.014",
language = "English (US)",
volume = "36",
pages = "9--23",
journal = "Developmental Cell",
issn = "1534-5807",
publisher = "Cell Press",
number = "1",
}